Unknown

Dataset Information

0

Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial.


ABSTRACT: Purpose. Survival following biochemical failure is highly variable. Using a randomized trial dataset, we sought to define a risk stratification scheme in men with locally advanced prostate cancer (LAPC). Methods. The TROG 96.01 trial randomized 802 men with LAPC to radiation?±?neoadjuvant androgen suppression therapy (AST) between 1996 and 2000. Ten-year follow-up data was used to develop three-tier post-biochemical failure risk stratification schemes based on cutpoints of time to biochemical failure (TTBF) and PSA doubling time (PSADT). Schemes were evaluated in univariable, competing risk models for prostate cancer-specific mortality. The performance was assessed by c-indices and internally validated by the simple bootstrap method. Performance rankings were compared in sensitivity analyses using multivariable models and variations in PSADT calculation. Results. 485 men developed biochemical failure. c-indices ranged between 0.630 and 0.730. The most discriminatory scheme had a high risk category defined by PSADT??9 months or TTBF?>?3 years. Conclusion. TTBF and PSADT can be combined to define risk stratification schemes after biochemical failure in men with LAPC treated with short-term AST and radiotherapy. External validation, particularly in long-term AST and radiotherapy datasets, is necessary.

SUBMITTER: Steigler A 

PROVIDER: S-EPMC3540903 | biostudies-other | 2012

REPOSITORIES: biostudies-other

altmetric image

Publications

Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial.

Steigler Allison A   Denham James W JW   Lamb David S DS   Spry Nigel A NA   Joseph David D   Matthews John J   Atkinson Chris C   Turner Sandra S   North John J   Christie David D   Tai Keen-Hun KH   Wynne Chris C  

Prostate cancer 20121224


Purpose. Survival following biochemical failure is highly variable. Using a randomized trial dataset, we sought to define a risk stratification scheme in men with locally advanced prostate cancer (LAPC). Methods. The TROG 96.01 trial randomized 802 men with LAPC to radiation ± neoadjuvant androgen suppression therapy (AST) between 1996 and 2000. Ten-year follow-up data was used to develop three-tier post-biochemical failure risk stratification schemes based on cutpoints of time to biochemical fa  ...[more]

Similar Datasets

| S-EPMC10461311 | biostudies-literature
| S-EPMC3829011 | biostudies-literature
| S-EPMC8185652 | biostudies-literature
| S-EPMC9978213 | biostudies-literature
| S-EPMC9684888 | biostudies-literature
| S-EPMC9253070 | biostudies-literature
| S-EPMC10539304 | biostudies-literature
| S-EPMC7807327 | biostudies-literature
| S-EPMC10453281 | biostudies-literature
| S-EPMC7614721 | biostudies-literature